Previous close | 1,364.80 |
Open | 1,367.40 |
Bid | 1,380.20 x 0 |
Ask | 1,380.60 x 0 |
Day's range | 1,360.86 - 1,384.00 |
52-week range | 1,284.00 - 1,847.00 |
Volume | 6,179,771 |
Avg. volume | 10,471,368 |
Market cap | 69.424B |
Beta (5Y monthly) | 0.32 |
PE ratio (TTM) | 10.93 |
EPS (TTM) | 126.30 |
Earnings date | 03 Feb 2021 |
Forward dividend & yield | 0.76 (5.57%) |
Ex-dividend date | 12 Nov 2020 |
1y target est | 1,644.50 |
The falling GlaxoSmithKline share price makes today's valuation look attractive, and the generous 5.86% yield is also tempting. So what's my problem? The post Should I ignore the falling GlaxoSmithKline share price and pocket its 6% yield anyway? appeared first on The Motley Fool UK.
Glaxo (GSK) and J&J's (JNJ)get FDA approval for Cabenuva, a once-monthly injectable regimen of cabotegravir and rilpivirine, for the treatment of adults with virally suppressed HIV-1 infection.
Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.